Home/Investors/Redmile Group

Redmile Group

Biotech Investor · 7 portfolio companies

Portfolio

7

Combined Value

$5.8B

Focus Areas

15

Top Stage

Phase 3

Investment Focus

Neuromuscular Cardiometabolic Oncology Fibrosis Hematology Allergy & Immunology Inflammatory Diseases Fibrotic Diseases Genetics & Genomics Rare Disease Neuroscience Infectious Disease Huntington's Disease Genetic Disorders Immunology

Portfolio Companies

Company	Stage	Valuation	Focus
Scholar Rock	Phase 3	$5.6B	Neuromuscular, Cardiometabolic
Third Harmonic Bio	Phase 1b	$240M	Allergy & Immunology, Inflammatory Diseases
Ascidian Therapeutics	preclinical	—	Genetics & Genomics, Rare Disease
Clear Labs	Commercial	—	Oncology, Infectious Disease
ElevateBio	Pre-clinical	—	Huntington's Disease, Genetic Disorders
Excision BioTherapeutics	Phase 1	—	Infectious Disease, Genetic Disorders
Strand Therapeutics	phase-1	—	Oncology, Immunology

Frequent Co-Investors

OrbiMed1 shared Atlas Venture1 shared ARCH Venture Partners1 shared GV1 shared Apple Tree Partners1 shared Vertex Ventures HC1 shared Polaris Partners1 shared Timothy Springer1 shared